Why is Teva buying BioXcel assets after its bankruptcy filing?

Teva is pursuing BioXcel’s assets through bankruptcy for $57.5 million upfront, which looks more like a distressed-asset purchase than a traditional growth acquisition. The deal suggests Teva sees selective strategic value in certain programs while avoiding the risk and cost of taking on BioXcel’s full operating platform.